Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 36 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 12 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 350 [iu] in 0.42 ml - follistim® aq cartridge (follitropin beta) injection, is indicated: in women for: prior to initiation of treatment with follistim aq cartridge: - women should have a complete gynecologic and endocrinologic evaluation. - primary ovarian failure should be excluded. - the possibility of pregnancy should be excluded. - tubal patency should be demonstrated. - the fertility status of the male partner should be evaluated. prior to initiation of treatment with follistim aq cartridge: - women should have a complete gynecologic and endocrinologic evaluation and diagnosis of cause of infertility. - the possibility of pregnancy should be excluded. - the fertility status of the male partner should be evaluated. in men for: prior to initiation of treatment with follistim aq cartridge: - men should have a complete medical and endocrinologic evaluation. - hypogonadotropic hypogonadism should be confirmed and primary testicular failure should be excluded. - serum testosterone levels should be normalized with human chorionic

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: poloxamer; phosphoric acid; sucrose; dibasic sodium phosphate dihydrate; water for injections; methionine; metacresol; sodium hydroxide; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: methionine; phosphoric acid; dibasic sodium phosphate dihydrate; sodium hydroxide; poloxamer; sucrose; metacresol; water for injections; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 600 iu/ml - injection, solution - excipient ingredients: methionine; phosphoric acid; dibasic sodium phosphate dihydrate; water for injections; sucrose; poloxamer; sodium hydroxide; metacresol; monobasic sodium phosphate monohydrate - the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies. gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - powder and solvent for solution for injection - follitropin alfa 150 iu; lutropin alfa 75 iu - follitropin alfa - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - solution for injection - corifollitropin alfa 100 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - solution for injection - corifollitropin alfa 150 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - corifollitropin alfa, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sucrose; polysorbate 20; water for injections; methionine; hydrochloric acid - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.